(redirected from Ofirmev)
Also found in: Thesaurus, Medical, Encyclopedia.


 (ə-sē′tə-mĭn′ə-fən, ăs′ə-)
A crystalline compound, C8H9NO2, used in medicine to relieve pain and reduce fever. Also called paracetamol.


(Pharmacology) a US name for paracetamol


(əˌsi təˈmɪn ə fən, ˌæs ɪ tə-)

a crystalline substance, C8H9NO2, used as a headache and pain reliever and to reduce fever.
[1955–60; acet- + amino- + phen (ol)]
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.acetaminophen - an analgesic for mild pain but not for inflammationacetaminophen - an analgesic for mild pain but not for inflammation; also used as an antipyretic; (Datril, Tylenol, Panadol, Phenaphen, Tempra, and Anacin III are trademarks of brands of acetaminophen tablets)
analgesic, anodyne, pain pill, painkiller - a medicine used to relieve pain


n acetaminofén m, acetaminofeno, paracetamol m (INN)
References in periodicals archive ?
Mallinckrodt plc, a leading global specialty pharmaceutical company, announced results from two retrospective, claims-based analyses providing health economic insights on the use of OFIRMEV (acetaminophen) injection intravenous (IV) acetaminophen versus oral acetaminophen for managing postoperative pain in patients undergoing bariatric surgery or appendectomy.
Acthar Gel (repository corticotrophin injection) and Therakos Immunotherapy platform, OFIRMEV (acetaminophen injection), and INOMAX (nitric oxide) gas, for inhalation.
M2 PHARMA-November 9, 2016-Mallinckrodt receives US FDA approval for OFIRMEV IV bag presentation
M2 EQUITYBITES-November 9, 2016-Mallinckrodt receives US FDA approval for OFIRMEV IV bag presentation
The Journal cites similar increases for Ofirmev pain injections and Vimovo pain tablets after new companies acquired the rights.
Acthar gel is expected to complement Mallinckrodt's growth portfolio of leading specialty pharmaceutical brands, including Ofirmev, Exalgo and Xartemis XR.
As a result, the US maker of the OFIRMEV pain product became an indirect, fully-owned unit of Mallinckrodt and will cease trading on Nasdaq.
and Canadian rights to Ofirmev in 2006 from Bristol-Myers Squibb Co.
Cadence will use the funds to back the introduction of its OFIRMEV acute pain and fever treatment product, which is currently marketed in Europe.
Candence Pharmaceuticals (Nasdaq: CADX) has an early November PDUFA date and expected FDA decision for OFIRMEV (intravenous or IV acetaminophen).